Guggenheim reaffirmed their positive rating on shares of Valeant Pharmaceuticals International Inc. (NYSE:VRX) in a research report released on Tuesday. The firm currently has a $55.00 target price on the specialty pharmaceutical company’s stock.

Other equities research analysts have also recently issued research reports about the company. Rodman & Renshaw reaffirmed a buy rating and issued a $90.00 price target on shares of Valeant Pharmaceuticals International in a report on Thursday, July 28th. Jefferies Group reissued a buy rating and set a $40.00 target price on shares of Valeant Pharmaceuticals International in a research note on Wednesday, August 10th. TD Securities reissued a buy rating and set a $38.00 target price on shares of Valeant Pharmaceuticals International in a research note on Saturday, August 13th. Canaccord Genuity reissued a hold rating and set a $28.00 target price on shares of Valeant Pharmaceuticals International in a research note on Monday, August 1st. Finally, JPMorgan Chase & Co. set a $35.00 target price on Valeant Pharmaceuticals International and gave the stock a hold rating in a research note on Monday, July 25th. Four research analysts have rated the stock with a sell rating, fifteen have given a hold rating, eight have given a buy rating and one has given a strong buy rating to the stock. The stock has an average rating of Hold and an average target price of $40.18.

Shares of Valeant Pharmaceuticals International (NYSE:VRX) opened at 16.82 on Tuesday. The company’s 50 day moving average price is $22.29 and its 200-day moving average price is $25.33. Valeant Pharmaceuticals International has a 52 week low of $13.77 and a 52 week high of $119.87. The stock’s market capitalization is $5.85 billion.

Valeant Pharmaceuticals International (NYSE:VRX) last posted its quarterly earnings results on Tuesday, November 8th. The specialty pharmaceutical company reported $1.55 EPS for the quarter, missing the consensus estimate of $1.78 by $0.23. Valeant Pharmaceuticals International had a negative net margin of 22.17% and a positive return on equity of 41.02%. The company earned $2.48 billion during the quarter, compared to analyst estimates of $2.49 billion. During the same period in the prior year, the business posted $2.74 EPS. Valeant Pharmaceuticals International’s revenue for the quarter was down 11.0% compared to the same quarter last year. Equities research analysts predict that Valeant Pharmaceuticals International will post $6.45 EPS for the current year.

A number of large investors have recently bought and sold shares of the stock. Tower Research Capital LLC TRC raised its stake in Valeant Pharmaceuticals International by 6.7% in the second quarter. Tower Research Capital LLC TRC now owns 6,405 shares of the specialty pharmaceutical company’s stock worth $129,000 after buying an additional 402 shares during the last quarter. Kistler Tiffany Companies LLC raised its stake in Valeant Pharmaceuticals International by 95.5% in the third quarter. Kistler Tiffany Companies LLC now owns 5,567 shares of the specialty pharmaceutical company’s stock worth $137,000 after buying an additional 2,719 shares during the last quarter. US Bancorp DE raised its stake in Valeant Pharmaceuticals International by 141.0% in the third quarter. US Bancorp DE now owns 5,745 shares of the specialty pharmaceutical company’s stock worth $141,000 after buying an additional 3,361 shares during the last quarter. Cacti Asset Management LLC raised its stake in Valeant Pharmaceuticals International by 68.0% in the second quarter. Cacti Asset Management LLC now owns 8,400 shares of the specialty pharmaceutical company’s stock worth $169,000 after buying an additional 3,400 shares during the last quarter. Finally, AGF Investments Inc. raised its stake in Valeant Pharmaceuticals International by 121.9% in the second quarter. AGF Investments Inc. now owns 8,842 shares of the specialty pharmaceutical company’s stock worth $178,000 after buying an additional 4,857 shares during the last quarter. 64.39% of the stock is currently owned by hedge funds and other institutional investors.

Valeant Pharmaceuticals International Company Profile

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

5 Day Chart for NYSE:VRX

Receive News & Stock Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related stocks with our FREE daily email newsletter.